Arne Christian Rufer

Arne C. Rufer holds a PhD in biochemistry from the University of Cologne, for which he elucidated the crystal structure of the diabetes target carnitine palmitoyltransferase 2 (CPT-2) in close collaboration with F. Hoffmann-La Roche Ltd. During his postdoc time at the Max-Planck-Institute for Medical Research, he used biophysical methods to characterize binding modes of adaptor proteins. After returning to F. Hoffmann-La Roche Ltd, he continued to link biochemical and biophysical approaches for target assessment (TA), lead identification (LI) and lead optimization (LO) in various roles. He founded a Mechanistic Enzymology group for the purpose of assay development and druggability assessment of enzyme drug targets, supporting multiple LI and LO campaigns. He was Section Head, Biochemistry & Biophysics, Science & Technology Lead in the Lead Discovery department, and recently took on a new role to lead a chemical biology initiative in the Medicinal Chemistry department. His interest and contributions in chemical biology focus on chemical probes and activity-based protein profiling (ABPP).